Branded Legacy Subsidiary Partners with McMaster University to Evaluate Addiction Interventions

Branded Legacy, Inc. (OTC: BLEG) announced that its wholly owned subsidiary, Bio-Legacy Evaluative Group, has partnered with McMaster University to evaluate innovative products for populations affected by addictions. The collaboration combines McMaster's expertise in addiction medicine, clinical trials, and guideline development with Bio-Legacy's real-world scientific experience to advance rigorous evaluations, clinical trials, and regulatory submissions.

This partnership supports the development of accessible, cost-effective interventions aimed at reducing overdose deaths, minimizing drug-related harms, and promoting long-term recovery. The initiative addresses the critical need for evidence-based solutions in addiction treatment, particularly as overdose rates continue to rise globally. By leveraging academic research capabilities with industry experience, the collaboration aims to accelerate the validation and deployment of effective treatments.

Branded Legacy focuses on health and wellness solutions, particularly in combating addiction through innovative approaches. The company's patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment, representing a significant advancement in emergency response technology. This platform also enables nasal delivery of vaccines and other medications, creating opportunities in global markets for rapid pandemic response and improved access in underserved regions.

The partnership with McMaster University represents a strategic move to validate and scale these innovations through rigorous scientific evaluation. For more information about the company's initiatives, visit https://BrandedLegacy.com. The collaboration underscores the growing importance of public-private partnerships in addressing complex health challenges, particularly in the addiction treatment space where evidence-based interventions are urgently needed.